A clinical trial of a cannabis extract to treat patients with Asthma and Chronic Obstructive Pulmonary Disease (COPD) Overlap Syndrome (ACOS).
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2017
Price : $35 *
At a glance
- Drugs CS TATI-1 (Primary)
- Indications Respiratory tract disorders
- Focus Adverse reactions
- 30 Nov 2017 New trial record
- 28 Nov 2017 According to a Cannabis Science media release, soon the company will initiate this trial for to treat patients with Asthma and COPD Overlap Syndrome (ACOS)).